Everolimus approval now includes prevention of liver transplant rejection Clinical Endocrinology News Digital Network The approved indication states that in liver transplant recipients, everolimus is used in combination with the calcineurin inhibitor tacrolimus (at a reduced dose) and corticosteroids, and that it should be administered no earlier than 30 days post ... |
